TABLE 1.
Correlation of DRD1 expression with the clinicopathological characteristics in 221 patients with HCC 1
| DRD1 protein | ||||
|---|---|---|---|---|
| Characteristics | Total no. of cases | Low expression (case, n[%]) | High expression (case, n[%]) | P Value |
| Gender | ||||
| Female | 31 | 9 (29.0) | 22 (71.0) | |
| Male | 190 | 78 (41.1) | 112 (58.9) | 0.204 |
| Age (years) | ||||
| ≤ 50 | 120 | 51 (42.5) | 69 (57.5) | |
| > 50 | 101 | 36 (35.6) | 65 (64.4) | 0.299 |
| HBsAg | ||||
| Negative | 27 | 16 (59.3) | 11 (40.7) | |
| Positive | 194 | 71 (36.6) | 123 (63.4) | 0.024 |
| Child‐Pugh classification 2 | ||||
| A | 218 | 87 (39.9) | 131 (60.1) | |
| B | 3 | 0 (0) | 3 (100) | 0.160 |
| AFP (ng/mL) | ||||
| < 20 | 78 | 29 (37.2) | 49 (62.8) | |
| 20‐400 | 53 | 19 (35.8) | 34 (64.2) | |
| >400 | 90 | 39 (43.3) | 51 (56.7) | 0.599 |
| GGT (units/L) | ||||
| ≤ 50 | 104 | 42 (40.4) | 62 (59.6) | |
| > 50 | 117 | 45 (38.5) | 72 (61.5) | 0.770 |
| Tumour size (cm) | ||||
| ≤ 5 | 103 | 41 (39.8) | 62 (60.2) | |
| > 5 | 118 | 46 (39.0) | 72 (61.0) | 0.901 |
| Satellite nodule | ||||
| Absent | 189 | 80 (42.3) | 109 (57.7) | |
| Present | 32 | 7 (21.9) | 25 (78.1) | 0.029 |
| Tumour capsule | ||||
| Absent | 69 | 29 (42.0) | 40 (58.0) | |
| Present | 152 | 58 (38.2) | 94 (61.8) | 0.585 |
| Vascular invasion | ||||
| Absent | 196 | 79 (40.3) | 117 (59.7) | |
| Present | 25 | 8 (32.0) | 17 (68.0) | 0.423 |
| Cirrhosis | ||||
| Absent | 40 | 17 (42.5) | 23 (57.5) | |
| Present | 181 | 70 (38.7) | 111 (61.3) | 0.654 |
| TNM classification 3 | ||||
| I / II | 184 | 79 (42.9) | 105 (57.1) | |
| III / IV | 37 | 8 (21.6) | 29 (78.4) | 0.015 |
1
Values of statistical significance are in bold.
2
There is no patient with Child‐Pugh Class C.
3
Tumor node metastasis (TNM) was evaluated based on the seventh edition of the American Joint Committee on Cancer (AJCC).
Abbreviations: DRD1, dopamine receptor D1. HCC, hepatocellular carcinoma. AFP, Alpha‐fetoprotein. GGT, Gamma‐glutamyl transferase. TNM, Tumor Node Metastasis.